HOME >> BIOLOGY >> NEWS
Nabi reports successful reduction in S. aureus bacteremias at Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

Toronto, Canada , September 19, 2000 -- Nabi (Nasdaq: NABI) announced preliminary results from the phase III clinical trial for StaphVAX™ (Staphylococcus aureus conjugate vaccine) at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Toronto, Canada. The data from the trial demonstrated a dramatic reduction in S. aureus bacteremias (blood stream infections) during the first ten months of the study. However, the decrease in bloodstream infections after one-year follow up, the primary endpoint for the study, did not achieve statistical significance. The study was performed by the Kaiser Permanente Vaccine Study Center based in Oakland, CA, and the preliminary results were presented by the principal investigators from that institution, Steven Black, M.D. and Henry Shinefield, M.D.

"We are excited by the data from this trial," said David J. Gury, Chairman, President and Chief Executive Officer of Nabi. "Based on the protection exhibited for StaphVAX treated patients during the first ten months of the trial, we strongly believe that a CPS-conjugated vaccine against S. aureus is feasible. Moreover, the demonstration that StaphVAX-induced antibodies can protect against bloodstream infections has very positive implications for the success of Nabi's entire Gram-positive program."

In reviewing the preliminary results from the trial, Dr. Black stated, "Through ten months, the study results found 57% fewer cases of Staph aureus disease in these immune compromised study participants who received the vaccine. Staph aureus is an increasing, lethal bacteria, which causes significant morbidity and mortality."

Dr. Shinefield affirmed, "These results are particularly important at a time of growing resistance of Staph aureus to antibiotics."

StaphVAX consists of capsular polysaccharides (CPS) from the two most common serotypes of S. aureus (Type 5 and Type 8), each conjugated to a carrier protein. The double-blinded, placebo-
'"/>

Contact: Joan Kureczka
JKureczka@aol.com
415-821-2413
Kureczka/Martin Associates
18-Sep-2000


Page: 1 2

Related biology news :

1. APP reports Abraxane(TM) is active in breast cancer patients who failed taxol or taxotere
2. Scientists question reports of massive ant supercolonies in California and Europe
3. Survey reports fall in stem cell transplants for breast cancer
4. VaxGen reports Phase I clinical trial results of anthrax vaccine candidate
5. Immerge reports PERVs most infectious to human cells not part of germ-line DNA of mini-swine
6. By the year 2050, human population could add 2.6 billion people, reports Rockefeller scientist
7. Measles on the rise as vaccinations fall in the UK, Science study reports
8. WCS biologist George Schaller reports surprising increase in Tibets wildlife
9. Clinical study reports findings of combination therapy with DOXIL
10. Europes population has developed new tendency to shrink, Science study reports
11. U of A scientist finds Atlantic salmon escapes higher than government reports

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/21/2020)... ... August 20, 2020 , ... NDA ... , a Clinical Operations executive with expertise in clinical trial planning and feasibility, ... as an Expert Consultant. Throughout his career, Mr. Movahhed has helped design and ...
(Date:8/7/2020)... ... August 06, 2020 , ... Alucio™, ... to announce that Eric Chen and Jessica Wong have joined the company’s leadership ... Strategy, respectively. , Eric Chen heads development efforts for Alucio’s flagship product, Beacon, ...
(Date:8/3/2020)... PHOENIX (PRWEB) , ... August 03, 2020 , ... ... the company announced a new partnership with medical equipment manufacturer, Spectrum Solutions, to ... its clients to strengthen their laboratory supply chain for more than 10 years. ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... July 29, 2020 , ... eSource has long been touted ... will cover the history of eSource, the reasons it did not take off as ... to site source, the industry is moving towards capturing data electronically for clinical trials ...
(Date:7/22/2020)... ... July 22, 2020 , ... Join experts from Reed Tech , Gary ... in a one hour live webinar on Thursday, August 13, 2020 at ... drugs and medical devices. Specifically, for medical devices, the NMPA has departments dealing with ...
(Date:7/18/2020)... ... 2020 , ... Medial EarlySign , a leader in ... high-burden diseases, and Centric Consulting, a business and technology consulting firm, today announced ... in order to identify and prioritize patients for care. , Combining Centric’s management ...
(Date:7/10/2020)... BALTIMORE (PRWEB) , ... July ... ... Baltimore biotechnology company, announced today that Massachusetts Institute of Technology (MIT) has ... This broader license allows PathSensors to move into the point-of-care diagnostic market, ...
Breaking Biology Technology:
Cached News: